NCT06023966Completed
A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery
A Clinical Prospective Study to Validate a Risk Scoring Model for the Hepatic Metastases From Gastric Cancer After Curative Surgery
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
A previous study of investigators established a risk scoring model for occurrence of postoperative hepatic metastases in patients who underwent curative gastrectomy directly without neoadjuvant therapy. In order to further validate the clinical applicability of abovementioned model, investigators designed this prospective study, which also included patients who received neoadjuvant therapy before surgery, with the aim of exploring the applicability of the risk scoring model to this group of patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 120 (actual)
- First submitted
- 29 Aug 2023
- Start date
- Sept 2023
- Primary completion date
- Aug 2025
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06023966
What you commit to
- Study type: Observational
- Participants enrolled: 120
- From Sept 2023 to the primary completion date, Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Immunosuppressive therapists for organ transplantation;
- Concurrent participation in other clinical trials.
Other illness
- Special histological types of gastric cancer (neuroendocrine, squamous, squamous cell, hepatoid adenocarcinoma or others);
- Gastro-esophageal junction cancer;
- Severe congestive heart failure, frequent arrhythmia, or myocardial infarction within 12 months;
- Seriously uncontrolled recurrent infection;
- History of other malignancies;
- No abilities of self-knowledge or mental disorders;
- Combination of other serious diseases;
Who the study is looking for
- Received curative gastrectomy (D2 lymph node dissection);
- Gastric cancer without distant organ metastasis, distant lymph node metastasis and peritoneal implantation (M0) confirmed by postoperative pathology;
- No hepatic tumors and other occupying diseases, no chronic diseases such as cirrhosis and hepatitis, no hepatic schistosomiasis, no hepatic echinococcosis, no hepatic tuberculosis, and no severe fatty liver disease before the curative surgery;
- No history of intraperitoneal chemotherapy;
- No other serious concomitant diseases with satisfactory organ function;
- No history of other malignant tumors;
- Comply with the protocol during the whole study period;
- Sign informed consent and permission of withdraw in the whole study period;
- Estimation the overall survival after surgery no less than 12 months;
- Consent to analysis of clinicopathological data and prognostic follow up;
- Karnofsky Performance Scores (KPS) more than 60.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Hospital of Tianjin Medical University Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.